T. Thomsen

发表

The Effect of Therapeutic and Supratherapeutic Oral Doses of Nomegestrol Acetate (NOMAC)/17β-Estradiol (E2) on QTcF Intervals in Healthy Women: Results from a Randomized, Double-Blind, Placebo- and Positive-Controlled Trial

T. Post, P. De Kam, J. V. van Kuijk, 2014, Clinical Drug Investigation.

Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity

W. Haefeli, G. Mikus, J. Burhenne, 2013, Journal of clinical pharmacology.

Pharmacokinetics of Levetiracetam in Patients with Moderate to Severe Liver Cirrhosis (Child‐Pugh Classes A, B, and C): Characterization by Dynamic Liver Function Tests

J. Brockmöller, I. Roots, H. Lochs, 2005, Clinical pharmacology and therapeutics.

Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size.

E. F. Smith, K. Schrör, T. Thomsen, 1984, Cardiovascular research.

Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics

W. Haefeli, I. Walter‐Sack, G. Mikus, 2005, Clinical pharmacology and therapeutics.

The effect of food composition on serum testosterone levels after oral administration of Andriol® Testocaps®

T. Thomsen, W. Bagchus, P. G. Schnabel, 2007, Clinical endocrinology.

Effects of Sugammadex Doses up to 32 mg/kg Alone or in Combination with Rocuronium or Vecuronium on QTc Prolongation

T. Thomsen, P. Peeters, M. Prohn, 2010, Clinical drug investigation.

Preclinical and Clinical Studies with Galanthamine

G. Holl, T. Thomsen, M. Straschill, 1991 .

Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice

W. Weber, T. Thomsen, U. Bickel, 1991, Neuropharmacology.

Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals.

M. E. Olsen, H. Dige-Petersen, C. Hassager, 1999, American journal of hypertension.

Omeprazole weakly inhibits CYP1A2 activity in man.

U. Fuhr, J. Brockmöller, I. Roots, 1999, International journal of clinical pharmacology and therapeutics.

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

T. Thomsen, H. Kewitz, 1990, Life sciences.

Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials.

G. Holl, T. Thomsen, M Straschill, 1992, Electroencephalography and clinical neurophysiology.

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

P. Goss, T. Thomsen, J. Banké-Bochita, 2007, Breast Cancer Research.

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

Gerd Mikus, Walter E Haefeli, W. Haefeli, 2006, Clinical pharmacology and therapeutics.

Single IV sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium are not associated with QTc prolongation: 9AP5-9

T. Thomsen, P. Peeters, M. Prohn, 2008 .

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

P. De Kam, J. V. van Kuijk, T. Thomsen, 2012, International journal of clinical pharmacology and therapeutics.

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans

T. Thomsen, U. Bickel, J. Fischer, 2004, European Journal of Clinical Pharmacology.

Estimation of Cholinesterase Activity (EC 3.1.1.7; 3.1.1.8) in Undiluted Plasma and Erythrocytes as a Tool for Measuring In Vivo Effects of Reversible Inhibitors

T. Thomsen, H. Kewitz, O. Pleul, 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers.

T. Thomsen, J. Fischer, H. Kewitz, 1991, Biochemical pharmacology.

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition

U. Bickel, W. Weber, T. Thomsen, 1991 .

Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine

H. Barz, T. Thomsen, U. Bickel, 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers

P. Goss, T. Thomsen, J. Banké-Bochita, 2004 .

Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring NuvaRing® with Oral Amoxicillin or Doxycycline in Two Randomised Trials

T. Thomsen, P. Dogterom, M. W. Heuvel, 2005, Clinical pharmacokinetics.

Galanthamine Hydrobromide in a Long-Term Treatment of Alzheimer's Disease

T. Thomsen, U. Bickel, H. Kewitz, 1990 .

Cardiovascular Actions In Vitro and Cardioprotective Effects In Vivo of Nileprost, a Mixed Type PGI2/PGE2 Agonist

H. Darius, T. Thomsen, K. Senior, 1987, Journal of cardiovascular pharmacology.

The effect of food composition on serum testosterone levels after oral administration of Andriol® Testocaps®

T. Thomsen, W. Bagchus, P. G. Schnabel, 2007, Clinical endocrinology.

The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6.

T. Thomsen, R. Bachus, U. Bickel, 1999, Pharmacogenetics.

A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors.

T. Thomsen, H. Kewitz, O. Pleul, 1989, Enzyme.